Should this produce one “best” clinic?
No. The purpose is to identify what can be verified, what remains unclear, and where independent medical or legal guidance may be necessary. It is not a provider ranking or endorsement.
Decision documentation / overseas options
Clinic Comparison Guide
A practical way for U.S. decision-makers to compare verifiable features of overseas ibogaine clinics without ranking providers, relying on promises, or treating a destination as a substitute for a safety plan.
01 / Start with the decision
Compare evidence, not atmosphere
A clinic is not established by a polished answer. It is established by details that can be checked.
Use this guide alongside the broader U.S. ibogaine decision context to keep legal status, travel, medical screening, and follow-up in the same frame. It is designed for notes, questions, and unresolved items—not for declaring any provider safe or appropriate.
Ibogaine is a psychoactive substance derived from plants in the iboga botanical tradition, but botanical origin does not answer the clinical questions that matter in a treatment setting. A decision should remain open to the possibility that an option is not verifiable enough to pursue.
For context before comparing overseas options, review the practical framing in ibogaine in the United States and keep separate notes on what a clinic says from what an independent source can confirm.
02 / The comparison field
Features to document
Compare each clinic using the same categories. Ask for specifics, record the response in plain language, and mark what is documented versus what is only described.
- Legal and regulatory setting What country and local jurisdiction govern the facility? What can the clinic show about its operating status, and which professional rules apply to the people providing care?
- Qualifications and licensure Ask who is physically onsite, what each clinician’s role is, where each person is licensed, and how you can independently verify that information.
- Emergency capability Ask whether ECG monitoring, a defibrillator, oxygen, emergency medications, and a physician are onsite, who operates them, and what happens if a transfer is needed.
- Screening and interaction policies Request the pre-treatment evaluation process, medication review policy, cardiac screening approach, laboratory expectations, and reasons a person may be declined or deferred.
- Evacuation and continuity Ask for the medical evacuation plan, receiving-hospital pathway, travel support after discharge, aftercare plan, and how local U.S. continuity of care is handled.
- Consent and outcome transparency Request the consent materials before travel. Ask how complications, transfers, dropouts, and outcomes are recorded and whether the reporting method can be explained.
03 / Concrete proof wall
If a critical answer cannot be documented, record that gap. Do not fill it with optimism.
Medication interactions and cardiac history should be handled as clinical questions, not travel logistics. The FDA warning on ibogaine-related risks describes serious concerns, including cardiac risks, and reinforces why a clinic’s screening and escalation details deserve close attention.
Ask a clinic to describe its process rather than simply confirm that it is “safe.” A useful answer identifies the sequence, the responsible person, the available equipment, the threshold for stopping, and the next location of care. For a focused safety lens, use the risk considerations page as a companion while documenting those answers.
Legal status is also location-specific. A clinic’s willingness to operate does not itself establish a legal or regulated setting; compare its explanation with the questions raised by whether ibogaine is illegal before making travel commitments.
04 / Bunker panel
Questions worth asking
These prompts are templates, not a clinical assessment. Copy the answers exactly, including uncertainty, refusal, or a request to wait until arrival for details.
- Who will be onsite throughout screening, dosing, observation, and discharge—and how can I verify their current licensure?
- What cardiac and medication screening is required before I travel, who reviews it, and what findings would make you decline or postpone care?
- What monitoring and emergency equipment are immediately available, and who is authorized to respond if a serious complication occurs?
- Which hospital or emergency destination would be used, how is transport arranged, and what does the evacuation plan say about timing and responsibility?
- Can you provide informed-consent materials and your policies for medication changes, companions, discharge, complaints, complications, and follow-up before any deposit?
- How do you count and report outcomes, adverse events, transfers, and people who do not complete treatment?
Documentation checklist
- Save the sourceKeep a dated copy of written replies, policies, consent materials, credentials, and evacuation details.
- Separate claim from verificationWrite down what can be independently checked, including licensing, regulatory setting, and emergency arrangements.
- Use the same questionsAsk each clinic the same set of questions so differences in the answers are visible rather than buried in marketing language.
- Leave room for a noMissing paperwork, changing explanations, or pressure to decide quickly are findings to record—not details to excuse.
U.S. research alternatives: Research participation is distinct from overseas treatment. When studies are recruiting, their eligibility, consent, protocol, location, and follow-up requirements may differ substantially. ClinicalTrials.gov is a U.S. government database where listed studies can be checked directly; a listing is not a recommendation and does not guarantee enrollment.
For a fuller comparison between research pathways and travel decisions, place this checklist next to the step-by-step decision walkthrough rather than treating either one as a treatment recommendation.
05 / Context before commitment
Keep the comparison wide
A clinic comparison is only one part of a high-stakes decision. Travel, substance use, mental health, medical history, medications, support at home, and the possibility of emergency care all remain relevant.
Do not use cost, availability, or a rapid timeline to override missing safety information. If travel is being considered, the practical questions behind ibogaine treatment in Mexico and its cost should be documented alongside emergency logistics and plans for return home.
Alcohol-related decisions may require especially careful medication and withdrawal planning. The background on ibogaine treatment for alcohol can help organize questions, but it does not replace assessment by an appropriately qualified clinician.
Veterans and supporters may also be navigating service-related health needs, travel burdens, and local follow-up. Record those realities as part of the decision, and compare them with the context collected at ibogaine resources for veterans.
Be wary of treating supplements as interchangeable with clinical care or as a workaround for the same unanswered questions. Review the distinctions raised by ibogaine supplement information and preserve the same standard of evidence.
Claims about results need careful definitions: who was counted, for how long, against what outcome, and with what complications or loss to follow-up. Use that standard when reading ibogaine treatment success-rate claims or any clinic-provided testimonial material.
Duration also matters for travel and aftercare planning. The questions collected around how long ibogaine lasts can inform the timeline you ask a clinic to explain, including observation and discharge expectations.
Some people begin with a film or personal narrative. A documentary can surface perspectives, but it should not be used as a substitute for a clinic’s policies, consent materials, or medical records. Keep that distinction in mind when viewing the ibogaine documentary context.
Destination-focused information can help frame travel questions while still leaving provider-level details unresolved. For example, the material on ibogaine clinics in Costa Rica may help you identify what to ask about a specific setting, not which option to choose.
Directories may be a starting point for identifying facilities, but inclusion does not verify present-day staffing, emergency capability, or suitability. Treat listings such as ibogaine clinic directories as leads that still require direct, documented questions.
For clarity on how this independent resource approaches high-stakes decisions, see the principles behind Bright Basin 70. The purpose is to support a more legible decision—not to direct anyone toward a provider.
If an answer feels incomplete, return to the comparison categories, request a written clarification, and consider whether local medical or legal guidance is needed before travel. No single page can resolve the individual factors that may affect risk.
06 / Questions after the questions
A restrained conclusion
What if answers are vague or undocumented?
Treat missing detail as decision-relevant information. Pause, document the gap, ask follow-up questions, and do not convert marketing language into proof of an emergency capability or reported outcome.
Is U.S. research the same as overseas treatment?
No. Research participation, if available, has its own eligibility criteria, consent process, protocol, location, and follow-up expectations. Availability is not guaranteed.
Keep the record
Use the decision-support scope